Piper Sandler Cuts Inspire Medical Systems (NYSE:INSP) Price Target to $85.00

Inspire Medical Systems (NYSE:INSP) had its target price cut by Piper Sandler from $165.00 to $85.00 in a report published on Thursday, MarketBeat.com reports. They currently have an overweight rating on the stock.

Several other brokerages have also recently issued reports on INSP. Truist Financial cut shares of Inspire Medical Systems from a “buy” rating to a “hold” rating and set a $96.00 price objective on the stock. in a research note on Thursday, January 22nd. JPMorgan Chase & Co. lifted their target price on shares of Inspire Medical Systems from $82.00 to $118.00 and gave the company a “neutral” rating in a report on Tuesday, December 16th. Jefferies Financial Group reissued a “hold” rating and set a $85.00 price target (down from $160.00) on shares of Inspire Medical Systems in a report on Friday, October 24th. KeyCorp restated a “sector weight” rating on shares of Inspire Medical Systems in a research report on Tuesday, November 4th. Finally, Mizuho boosted their target price on Inspire Medical Systems from $110.00 to $130.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Five research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $108.94.

Inspire Medical Systems Stock Up 0.2%

Shares of NYSE:INSP opened at $59.78 on Thursday. Inspire Medical Systems has a 52-week low of $53.11 and a 52-week high of $197.75. The stock has a market cap of $1.74 billion, a P/E ratio of 12.00, a PEG ratio of 6.35 and a beta of 0.74. The business has a fifty day moving average of $92.88 and a two-hundred day moving average of $90.72.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Wednesday, February 11th. The company reported $1.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.96. The firm had revenue of $269.08 million for the quarter, compared to analyst estimates of $264.02 million. Inspire Medical Systems had a net margin of 15.95% and a return on equity of 10.96%. The business’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.15 earnings per share. On average, equities analysts anticipate that Inspire Medical Systems will post 2.16 earnings per share for the current year.

Insider Activity at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 2,000 shares of the company’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $127.48, for a total transaction of $254,960.00. Following the completion of the sale, the director directly owned 26,046 shares in the company, valued at $3,320,344.08. This represents a 7.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 4.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Inspire Medical Systems

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dragoneer Investment Group LLC raised its holdings in Inspire Medical Systems by 81.4% in the second quarter. Dragoneer Investment Group LLC now owns 2,354,411 shares of the company’s stock valued at $305,532,000 after acquiring an additional 1,056,808 shares in the last quarter. M&T Bank Corp acquired a new stake in shares of Inspire Medical Systems in the 4th quarter valued at about $85,871,000. Deerfield Management Company L.P. raised its stake in shares of Inspire Medical Systems by 648.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after purchasing an additional 907,694 shares in the last quarter. Morgan Stanley lifted its position in shares of Inspire Medical Systems by 179.5% during the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock worth $116,188,000 after purchasing an additional 809,121 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. acquired a new position in Inspire Medical Systems in the fourth quarter worth about $61,619,000. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Key Stories Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q4 beat: INSP reported $1.65 EPS vs. $0.69 expected and revenue of ~$269M, with expanded gross margins — a near-term operational positive. Zacks: INSP Beats Q4 Estimates
• Positive Sentiment: Some firms remain constructive at reduced targets — Mizuho and Piper Sandler kept outperform/overweight stances after lowering PTs, signaling there’s still perceived upside if reimbursement issues resolve. The Fly: Mizuho PT Cut
• Neutral Sentiment: Earnings call materials and transcript are available for detailed read-through (management commentary on coding, reimbursement and 2026 guide are key). Review to judge whether guidance risks are transitory. Seeking Alpha: Q4 Earnings Call Transcript
• Negative Sentiment: Management issued a 2026 revenue outlook of $950M–$1B and flagged a coding change plus reimbursement headwinds — the primary catalyst for the selloff risk and weaker forward expectations. MSN: 2026 Revenue Outlook & Coding Change
• Negative Sentiment: Multiple analyst downgrades and price-target cuts (Wells Fargo, Baird, Jefferies, Truist and others) followed the guidance and reimbursement concerns, increasing near-term selling pressure. Investing.com: Baird, Wells Fargo Cuts
• Negative Sentiment: The stock already experienced an earlier ~8% intraday decline after the coding/guidance news, showing how sensitive the market is to reimbursement updates. Investing.com: Shares Slide 8%

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.